(Q34016243)

30 July 2017

Safety of antiobesity drugs (English)

1 reference

30 July 2017

Bernard Man Yung Cheung

series ordinal

1

1 reference

PubMed ID

25114779

30 July 2017

Tommy Tsang Cheung

series ordinal

2

1 reference

PubMed ID

25114779

30 July 2017

Nithushi Rajitha Samaranayake

series ordinal

3

1 reference

30 July 2017

1 August 2013

1 reference

Therapeutic advances in drug safety

30 July 2017

1 reference

30 July 2017

4

1 reference

30 July 2017

4

1 reference

30 July 2017

171-181

1 reference

Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide

30 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Rise and fall of anti-obesity drugs

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Multicenter, placebo-controlled trial of lorcaserin for weight management

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

10-year follow-up of intensive glucose control in type 2 diabetes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Genome-wide association to body mass index and waist circumference: the Framingham Heart Study 100K project

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Safety of drug therapies used for weight loss and treatment of obesity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Effect of Orlistat in obese patients with heart failure: a pilot study.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Endocannabinoid control of food intake and energy balance

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Meta-analysis: pharmacologic treatment of obesity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Behavior and lifestyle: approaches to treatment of obesity.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

The endocannabinoid system and its therapeutic exploitation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

The obesity epidemic, metabolic syndrome and future prevention strategies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

The efficacy and safety of sibutramine for weight loss: a systematic review

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Obesity and hypertension: two epidemics or one?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

A benefit-risk assessment of sibutramine in the management of obesity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Mouse genetic approaches to feeding regulation: serotonin 5-HT2C receptor mutant mice.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

A low-carbohydrate as compared with a low-fat diet in severe obesity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Efficacy and safety of low-carbohydrate diets: a systematic review

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Multiple neural systems controlling food intake and body weight

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Diet, lifestyle, and the risk of type 2 diabetes mellitus in women

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Valvular heart disease associated with fenfluramine-phentermine

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Use and abuse of appetite-suppressant drugs in the treatment of obesity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4125319

Drug management of obesity--efficacy versus safety

5 July 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

Identification and Replication of a Novel Obesity Locus on Chromosome 1q24 in Isolated Populations of Cilento

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

A randomized double-blind placebo-controlled clinical trial of a product containing ephedrine, caffeine and other ingredients from herbal sources for treatment of overweight and obesity in the absence of lifestyle treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

The FDA's assessment of two drugs for chronic weight management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

Epilepsy and obesity in serotonin 5-HT2C receptor mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

Impairment of health and quality of life in people with large waist circumference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

Sibutramine. A review of its contribution to the management of obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

Raised interleukin-6 levels in obese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

Management of obesity in the National Health and Nutrition Examination Survey (NHANES), 2007-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

Effect of weight loss on blood pressure, arterial compliance, and insulin resistance in normotensive obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

A twin study of human obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098613489721

A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity

21 January 2018

1 reference

12 December 2020

Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study

1 reference

12 December 2020

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

12 December 2020

Novel pharmacotherapies for obesity poised to enter market

1 reference

12 December 2020

Pharmacotherapy for obesity

1 reference

12 December 2020

Mode of action of orlistat

1 reference

12 December 2020

Rimonabant for the treatment of obesity

1 reference

12 December 2020

Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients

1 reference

12 December 2020

Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective

1 reference

12 December 2020

Severe hepatic injury caused by orlistat

1 reference

12 December 2020

Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population

1 reference

12 December 2020

Drug treatment for obesity in the post-sibutramine era

1 reference

12 December 2020

Identifiers

DOI

10.1177/2042098613489721

1 reference

30 July 2017

1 reference

30 July 2017

1 reference

PubMed ID

25114779